Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Neuroblastoma Clinical Trial

Official title:

A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02982941
• Other study ID #: CP-MGA271-04
• Status: Completed
• Phase: Phase 1
• Start date: December 2016
• Est. completion date: May 22, 2019

Study information

• Verified date: February 2022
• Source: MacroGenics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors.

Description:

This study is a Phase 1, open-label, dose escalation and cohort expansion trial designed to characterize the safety, tolerability, PK, PD, immunogenicity and preliminary antitumor activity of enoblituzumab administered IV on a weekly schedule for up to 96 doses (approximately 2 years) in children and young adults with B7-H3-expressing relapsed or refractory malignant solid tumors. The study consists of a Dose Escalation Phase to determine the MTD (or MAD) of enoblituzumab followed by a Cohort Expansion Phase to further define the safety and initial antitumor activity of enoblituzumab. In the cohort expansion phase, 5 cohorts of 10 patients each will be enrolled to further evaluate the safety and potential efficacy of enoblituzumab administered at the MTD/MAD in patients with:1) neuroblastoma - measurable disease, 2) neuroblastoma - non-measurable disease, 3) rhabdomyosarcoma, 4) osteosarcoma, and 5) Ewing's sarcoma, Wilms' tumor, desmoplastic small round cell tumors, or malignant solid tumors of any other histology that test positive for B7-H3. All tumor evaluations will be carried out by both Response Evaluation Criteria in Solid Tumors (RECIST) and immune-related response criteria (irRC). Disease assessment in patients with neuroblastoma will use neuroblastoma overall response criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: May 22, 2019
• Est. primary completion date: May 22, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 35 Years

Eligibility

General Inclusion Criteria:

• Age at treatment 1 to 35 years.
• Relapsed or refractory malignant solid tumors of any histology for which no standard curative therapy is available (escalation phase).
• Histologically proven: neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma/ primitive neuroectodermal tumor, Wilms tumor, desmoplastic small round cell tumor or malignant solid tumors of any other histology that test positive for B7-H3 .
• Must have malignant solid tumors that demonstrate B7-H3 expression at 2+ or greater levels on the membranous surface of at least 10% of tumor cells or = 25% of tumor vasculature by IHC.
• With the exception of patients with non-measurable neuroblastoma patients must have measurable disease as per RECIST 1.1
• Karnofsky (patients = 16 years)/Lansky (patients < 16 years) index = 70.
• Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

• Patients are to be excluded from the study if they have any of the following:
• Patients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic.
• Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment within the past 2 years, and patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
• History of prior allogeneic bone marrow/stem-cell or solid organ transplantation.
• Patients receiving autologous stem cell transplantation must wait 8 weeks before initiation of study drug administration.
• Treatment with systemic chemotherapy or investigational therapy within 4 weeks of first study drug administration; other agents (e.g., biologics) within 2 weeks; radiation within 2 weeks; patients receiving 131I-MIBG therapy must wait 6 weeks prior to the initiation of study drug administration; corticosteroids (= 0.2 mg/kg/day prednisone or equivalent) or other immune suppressive drugs within the 2 weeks prior to the initiation of study drug administration.
• History of clinically significant cardiovascular disease
• Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.
• Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
• Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.
• Second primary invasive malignancy that has not been in remission for greater than 2 years.
• History of severe trauma or major surgery within 4 weeks prior to the initiation of study drug administration.
• Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for enoblituzumab
• Patients in Canada may not have a history or evidence of latent or active tuberculosis infection.

Related Conditions & MeSH terms

• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Neoplasms
• Neuroblastoma
• Osteosarcoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Ewing
• Wilms Tumor

Intervention

Drug:
• Enoblituzumab
enoblituzumab administered IV weekly for up to 96 weeks

Locations

Country	Name	City	State
United States	National Cancer Institute, Center for Cancer Research	Bethesda	Maryland
United States	Texas Children's Hospital	Houston	Texas
United States	University of Wisconsin, American Family Children's Hospital	Madison	Wisconsin
United States	Lucile Packard Children's Hospital, Stanford	Palo Alto	California
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Seattle Children's	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
MacroGenics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of enoblituzumab.	Adverse events, SAEs, incidence of treatment-emergent AE	Time of first dose through end of treatment (up to 2 years)
Secondary	Peak plasma concentration	PK of enoblituzumab	Time of first dose through end of treatment (up to 96 weeks)
Secondary	Number of participants that develop anti-drug antibodies	Proportion of patients who develop anti-MGA271 antibodies, immunogenicity	Time of first dose through end of treatment (up to 96 weeks)
Secondary	Antitumor activity of enoblituzumab	Anti-tumor activity of enoblituzumab using conventional RECIST 1.1 and immune related RECIST criteria	Time of first dose through end of treatment (up to 96 weeks)